Eli Lilly price target raised to $525 from $430 at Truist

Truist raised the firm’s price target on Eli Lilly to $525 from $430 and keeps a Buy rating on the shares. Eli Lilly is building a strong franchise in Alzheimer’s disease and diabetes/obesity led by donanemab and Mounjaro, with a robust pipeline of next-gen molecules, the analyst tells investors in a research note. The company’s donanemab shows compelling data in amyloid clearance and clinical benefit, but Truist thinks it will take time and experience for physicians and patients to navigate the diagnostic and treatment ecosystem.